Page 90 - 《中国药科大学学报》2025年第4期

486 学报 Journal of China Pharmaceutical University 2025, 56(4): 478 − 487 第 56 卷
A 1.5 ROS B 150 IL-6 C 3 NO

Relative fluorescence intensity (ROS) 1.0 pg/mL 90 Concentration/µM 2 1

120

60
0.5

0
Control TP5 30 0 0
Control TP5 (1 μg/mL) Control TP5 (1 μg/mL)
TP5 (0.1 μg/mL)
TP5 (10 μg/mL)
TP5 (0.1 μg/mL)
TP5 (10 μg/mL)
Figure 5 Effects of TP5 on the expression of effector molecules in MDSCs
A: Relative fluorescent intensity of ROS in cells from each group; B: Secretion levels of IL-6 in the cell supernatant from each group;
C: Secretion levels of NO in the cell supernatant from each group
A B Tumor weight

*
0.8 *
Control
0.6
TP5 (10 mg/kg)
Tumor weight/g 0.4
TP5 (20 mg/kg)

Lys-Asp-Leu-Tyr 0.2
(15 mg/kg)

0.0
Lys-Asp-Leu-Tyr
Control TP5 (10 mg/kg) TP5 (20 mg/kg) č15 mg/kgĎ

n.s.
C D
5 * 15 n.s.
*
4
Living of CD8 T cell/% 3 2 Living of CD4 T cell/% 10

1 5

0 0
Control TP5 Lys-Asp-Leu-Tyr Control TP5 Lys-Asp-Leu-Tyr

Figure 6 TP5 inhibits the growth of subcutaneous hepatocarcinoma through arginine regulation
A: Images of solid tumors in each group of mice at the experimental endpoint; B: Tumor weights in each group of mice; C: Proportion of
+
+
active CD8 T cells in each group; D: Proportion of active CD4 T cells in each group; *P < 0.05, **P < 0.01, ***P < 0.001 vs. the control
group. n.s., Not significant